When putting together your watch list, focus on stocks with an 80 or higher RS Rating. Alnylam Pharmaceuticals is one stock that just reached the mark, now earning a score of 85.
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against that of all other stocks.
Over 100 years of market history shows that the top-performing stocks tend to have an 80 or higher RS Rating as they begin their biggest price moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Alnylam Pharmaceuticals is working on a consolidation with a 304.39 entry. See if it can clear the breakout price in heavy trading.
The company reported 0% earnings growth in the latest quarterly report, while sales growth came in at -33%. Keep an eye out for the company's next round of numbers on or around Feb. 6.
Alnylam Pharmaceuticals holds the No. 83 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
